DCP
TLSI icon

Diameter Capital Partners’s TriSalus Life Sciences TLSI Stock Holding History

Diameter Capital Partners’s Portfolio TLSI Stock Details TLSI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-119,700
Closed -$1.19M – 170
2021
Q3 		$1.19M Hold
119,700
– – 0.11% 95
2021
Q2 		$1.16M Buy
119,700
+96,700
+420% +$948K 0.08% 110
2021
Q1 		$222K Buy
+23,000
New +$233K 0.02% 95

Other funds holding TLSI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HP
Hartree Partners New York $467M AUM 66.71% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Diameter Capital Partners's TLSI Position: Q4 2021 in Review

Diameter Capital Partners sold out of TriSalus Life Sciences (TLSI) in Q4 2021, closing a stake of 119,700 shares — an estimated $1.19M sold.

Diameter Capital Partners first reported a position in TLSI in Q1 2021 and held it in 3 quarters. The position peaked at $1.19M in Q3 2021. 68 funds tracked by Wall St. Rank hold TLSI as of Q4 2021.

  • Diameter Capital Partners reported no remaining TriSalus Life Sciences position as of Q4 2021 after selling out during the quarter.
  • Diameter Capital Partners sold 119,700 TriSalus Life Sciences shares in Q4 2021, an estimated $1.19M.
  • Diameter Capital Partners first reported a position in TriSalus Life Sciences in Q1 2021 and held it in 3 quarters.
  • Diameter Capital Partners's TriSalus Life Sciences position peaked at $1.19M in Q3 2021.
  • 68 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q4 2021.

Based on Diameter Capital Partners's 13F filing for Q4 2021, filed 15 Feb 2022.